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Background
Sodium–glucose cotransporter 2 inhibitors (SGLT2i) are
a novel antidiabetic class that inhibits glucose reabsorp-
tion and produce glycosuria. These medications are
being increasingly used as dual therapy with metformin
for type 2 diabetes (T2D) treatment, due to their benefi-
cial effect on weight and blood pressure. Three agents
are approved for clinical use and they may differ on
potency due to inhibition of only renal or both renal
and bowel glucose transportation.
Objective
to evaluate the efficacy of SGLT2i, dapagliflozin (DAPA),
canagliflozin (CANA) and empagliflozin (EMPA), on
HbA1c, weight and blood pressure (BP) in comparison
with placebo and other antidiabetic medications.
Materials and methods
MEDLINE, Cochrane central and EMBASE databases
were searched for randomized clinical trials (RCTs)
including patients with T2D allocated to SGLT2i for at
least 12 weeks. A direct and network meta-analysis
(NMA) were conducted.
Results
Thirty-nine RCTs were included (25.468 patients). CANA
300 mg, EMPA 25 mg and DAPA 10 mg were associated
with better g.lycemic control (HbA1c -1.01%, -0.69%,
-0.51%, respectively), and weight loss (-2.66 kg; -1.81 kg;
-1.80 kg, respectively) when compared to placebo. In
NMA, CANA 300 mg was superior to the others SGLT2i
for HbA1c (EMPA 25 mg: - 0.22% and DAPA 10 mg:
-0.26%), and weight (EMPA 25 mg: -1.06 kg and DAPA
10 mg: -0.84 kg). CANA 300 mg and DAPA 10 mg
decreased systolic BP (-4.77 mmHg and -2.66 mmHg,
respectively) and diastolic BP (-1.99 mmHg and
-1.76 mmHg, respectively) in comparison to placebo.
SGLT2i were similar to metformin and sulphonylurea
regarding to HbA1c, but superior to DPP4 inhibitors
(-0.15%) (Figure 1). Furthermore, SGLT2i were better than
metformin, sulphonylurea, and DPP4 inhibitors for reduc-
tion of weight (-1.04 kg, -4.76 kg and - 2.45 kg, respec-
tively) and systolic BP (-5.86 mmHg, -5.44 mmHg e
-4.43 mmHg, respectively). SGLT2i were also better than
sulphonylurea and DPP4 inhibitors for diastolic BP lower-
ing (-2.59 mmHg, -1.89 mmHg, respectively). Initial com-
bination of SGLT2i plus metformin resulted in greater
reduction of HbA1c than SGLT2 plus DPP4i (-0.53% vs.
-0.19%).
Conclusion
In T2D patients, SGLT2i were superior to placebo for
all outcomes analyzed, and CANA seems to be the most
potent among then. SGLT2i are as effective as metfor-
min and sulphonylurea and superior to DPP4 inhibitors
for HbA1c, but more potent than these classes regarding
weight and BP reduction.
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Figure 1 Effects of SGLT2i on HbA1c (A) and weight reducAon (B) compared to other antidiabetic medications
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